Cardiome and Merck release pivotal data for Brinavess IV
May 14, 2010 by leonardzehr · Leave a Comment
In a new Phase 3 study, Brinavess (vernakalant) intravenous, an investigational compound being developed in the European Union by Cardiome Pharma (NASDAQ: CRME; TSX: COM) and Merck (NYSE: MRK) to treat atrial fibrillation, was shown to be superior to amiodarone injection in converting patients’ heart rate from AF to sinus rhythm within 90 minutes of [...]
Listen to BioTuesdays 
